Announced
Completed
Oxford Biomedica completed the acquisition of ABL Europe from Institut Mérieux for €15m.
Synopsis
Oxford Biomedica, a quality and innovation-led cell and gene therapy CDMO, completed the acquisition of ABL Europe, a cell and gene therapy company, from Institut Mérieux, a microbiology company, for €15m.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.